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Abstract
Fusion of placental villous cytotrophoblasts with the overlying syncytiotrophoblast is essential for the maintenance of
successful pregnancy, and disturbances in this process have been implicated in pathological conditions such as pre-eclampsia
andintra-uterinegrowthretardation.InthisstudyweexaminedtheroleoftheRhoGTPasefamilymemberRhoEintrophoblast
differentiation and fusion using the BeWo choriocarcinoma cell line, a model of villous cytotrophoblast fusion. Treatment of
BeWo cells with the cell permeable cyclic AMP analogue dibutyryl cyclic AMP (dbcAMP) resulted in a strong upregulation of
RhoE at 24h, coinciding with the onset of fusion. Using the protein kinase A (PKA)-specific cAMP analogue N
6-phenyl-cAMP,
and a specific inhibitor of PKA (14–22 amide, PKI), we found that upregulation of RhoE by cAMP was mediated through
activation of PKA signalling. Silencing of RhoE expression by RNA interference resulted in a significant decrease in dbcAMP-
induced fusion. However, expression of differentiation markers human chorionic gonadotrophin and placental alkaline
phosphatasewasunaffectedbyRhoE silencing.Finally,wefoundthatRhoEupregulationbydbcAMPwassignificantlyreduced
under hypoxic conditions in which cell fusion is impaired. These results show that induction of RhoE by cAMP is mediated
through PKA and promotes BeWo cell fusion but has no effect on functional differentiation, supporting evidence that these
two processes may be controlled by separate or diverging pathways.
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Introduction
The syncytiotrophoblast layer of the human placenta is a large
multinucleated epithelium forming the outer surface of the
placental villi. It is in direct contact with maternal blood and is
the site of key placental functions such as nutrient and gas
exchange, and the synthesis of steroid and peptide hormones [1].
The formation, growth and maintenance of the syncytiotropho-
blast throughout pregnancy depends on continuous fusion with
underlying mononuclear villous cytotrophoblast stem cells [2].
Disturbances in fusion may be involved in pregnancy disorders
such as pre-eclampsia and intra-uterine growth retardation [3,4];
however, the mechanism by which it occurs remains poorly
understood. Isolated villous cytotrophoblasts aggregate and fuse in
vitro to form multinucleated syncytiotrophoblast [5] and this is
enhanced by treatment with cAMP, or with agents which increase
intracellular cAMP levels. A number of proteins have been
implicated in the fusion process, including envelope proteins
derived from human endogenous retroviruses (HERVs) [6] and
their receptors [7,8], glial cells missing 1 (GCM1) [9], connexin 43
[10] and ADAM proteins [6].
The Rho family of Ras-like GTPases comprises at least 23
signalling molecules involved in numerous cellular processes,
including proliferation, adhesion, migration and differentiation
[11], many of which involve regulation of the actin cytoskeleton
[12]. Most of these proteins are regulated by switching between an
active GTP-bound form and an inactive GDP-bound form,
controlled by guanine nucleotide exchange factors (GEFs) and
GTPase-activating proteins (GAPs) respectively [11]. Several
studies have described a role for Rho GTPases in trophoblast
processes such as cell migration [13] and cytoskeletal reorganiza-
tion [14] but no data have been reported on any possible role in
human cytotrophoblast fusion.
RhoE/Rnd3 is a member of the Rnd subfamily of Rho
GTPases, which also comprises Rnd1 and Rnd2 [15]. Unlike
other Rho GTPases, the members of this subfamily lack intrinsic
GTPase activity, do not bind GEFs and GAPs and therefore exist
predominantly in a constitutively active GTP-bound state. Hence,
their activity and function within the cell is regulated by their
expression level and localization. RhoE has been shown to
regulate cytoskeletal reorganisation and cell motility through
inhibition of RhoA activity [16], and plays a role in processes such
as cell proliferation and cell cycle progression [17,18], apoptosis
[19] and differentiation [20]. These various functions of RhoE
appear to be cell type- and context-dependent. A possible role for
RhoE in cell fusion has been demonstrated by the finding that, in
myoblasts, RhoE expression increases until the onset of cell fusion,
and this upregulation is required for the inhibition of RhoA and
ROCK1 activities and subsequent myoblast fusion [21]. In this
study we report for the first time that RhoE plays a role in human
cytotrophoblast fusion using the BeWo choriocarcinoma cell line,
a well characterised model which shares important properties with
freshly isolated human villous cytotrophoblasts, most significantly
the ability to fuse and form large multinucleated syncytia [22]. We
PLoS ONE | www.plosone.org 1 January 2012 | Volume 7 | Issue 1 | e30453show that RhoE is upregulated by cyclic AMP via activation of
protein kinase A, and that knockdown of RhoE by RNA
interference inhibits cell fusion. Finally, we show that RhoE
upregulation is attenuated under hypoxic conditions in which cell
fusion is impaired.
Materials and Methods
Ethics Statement
This study was approved by the Oxfordshire Research Ethics
Committee C.
Reagents
Dibutyryl cyclic AMP (dbcAMP) was obtained from Sigma,
UK. The PKA-selective cAMP analog N
6-phenyl-cAMP (Phe) was
obtained from Biolog Life Science Institute, Germany. PKA
inhibitor 14–22 amide (PKI) was purchased from Merck, UK.
Cell culture
BeWo cells and JEG-3 cells, both obtained from the European
Collection of Cell Cultures (Porton Down, UK), were cultured in
full growth medium (Dulbecco’s modified Eagle’s medium/Ham’s
F12 supplemented with 2 mM l-glutamine, 100 IU/ml penicillin,
100 mg/ml streptomycin (Sigma) and 10% (v/v) fetal calf serum
(Serum Laboratories International)). Cells were grown as a
monolayer at a density of 10
7 cells per 75 mm
2 flask at 37uCi n
95% air and 5% CO2, with medium changed every 48 h. For
passages, cells were detached with trypsin/EDTA (Life Technol-
ogies) at 37uC, then washed in complete culture medium and
replated.
Isolation of human primary villous cytotrophoblasts
Term placentae (n=3) were obtained with informed consent
after delivery by elective caesarean section in the John Radcliffe
Hospital, Oxford. Women with medical complications or previous
perinatal deaths were excluded. Only singleton pregnancies
without fetal abnormality or fetal growth restriction, i.e. .10th
centile, and $37 weeks gestation were included. Villous
cytotrophoblasts were prepared as described previously [23]. After
digestion partially pure cytotrophoblasts were isolated using a 5–
70% Percoll gradient (Amersham Biosciences UK). The fraction
between densities of 1.042 g and 1.068 g was aspirated, washed
with MEM-F (Minimum Essential Medium, Invitrogen, UK)
containing 1% antibiotic and antimycotic solution (Sigma) and
10% fetal calf serum and pooled, before cells were counted. Cells
were purified further by negative selection using immunomagnetic
beads (Dynabeads pan mouse IgG, Invitrogen) coupled to
antibodies raised against MHC class I (clone W6/32; Serotec,
UK), to remove non-trophoblast cells, and placental alkaline
phosphatase (PLAP) (NDOG2 [23]) to remove syncytial frag-
ments. Cell purity was analysed flow cytometrically as described
previously [23].
siRNA transfection
Cells were plated at 7.5x10
4 cells/ml into 24-well plates and
transfected immediately with RhoE siRNA (Hs_RND3_3, cat.
No. SI04286702, Qiagen) or a non-silencing negative control
siRNA (Allstars negative control, Qiagen) using Hiperfect
transfection reagent (Qiagen) following protocols provided by the
manufacturer. After 48h of incubation the cells were either
harvested for protein extraction and immunoblotting or treated as
described below for immunocytochemistry and analysis of cell
fusion.
Immunoblotting
Cells were washed with PBS and lysed directly into SDS–PAGE
loading buffer. Protein concentration was determined using a BCA
protein assay kit (Pierce). Proteins (5 mg) were resolved by SDS–
PAGE and transferred to PVDF membrane. Membranes were
then incubated in blocking buffer (Tris-buffered saline with 5%
BLOTTO (Santa Cruz) and 0.1% Tween) for 45 minutes at room
temperature then incubated with the appropriate primary
antibodies in blocking buffer overnight at 4uC. Reactions were
visualized by using a suitable secondary antibody conjugated to
horseradish peroxidase (Dako) in blocking buffer at room
temperature for 2 hours and an enhanced chemiluminescence
system (Pierce). Primary antibodies used were: anti-RhoE (#3664,
Cell Signaling Technology, 1:000), anti-b-actin (#ab6276, Ab-
cam, 0.15 mg/ml), anti-hCG (#ab14301, Abcam, 1 mg/ml) and
anti-placental alkaline phosphatase (NDOG2 [23], 1 mg/ml).
Immunocytochemistry
Cells for desmosomal protein staining were fixed with ice-cold
methanol and stored at 4uC in PBS until processing. Cells were
permeabilised by incubation in PBS containing 0.5% Triton-X
100 (Sigma) for 10 min at room temperature. All cells were
blocked for 1h at room temperature with PBS containing 10%
normal human serum and 0.1% Tween-20, then incubated
overnight at 4uC with a primary antibody to anti-desmosomal
protein (#D1286, Sigma, 10 mg/ml), diluted in blocking buffer
before washing (265 min) in PBS. Negative controls comprised
mouse IgG alone. Cells were next stained with Alexa Fluor 488
conjugated secondary antibody (Invitrogen) in blocking buffer, the
nuclei stained with Hoechst 33342 (1 mg/ml in PBS; Invitrogen)
and washed (265 min) and stored in PBS. They were examined
using a Leica DMIRE2 inverted fluorescence microscope and
photographed using a Hamamatsu Orca monochrome camera
and Simple PCI software (C Imaging).
Cell fusion analysis
Cells were induced to fuse by replacing full growth medium with
Dulbecco’s modified Eagle’s medium containing 2.5% (v/v) fetal
calf serum and 1mM dibutyryl cyclic AMP, as described
previously [24]. At the indicated time points the cells were washed
with PBS and fixed in methanol at 220uC for 10 minutes.
Intercellular boundaries were then visualized by immunocyto-
chemical staining with an antibody to desmosomal protein as
described above. Ten random fields containing approximately 300
nuclei each were photographed for subsequent analysis. Compos-
ite images of Hoechst 33342 stained nuclei and Alexa Fluor 488
stained desmosomal protein were made, then all nuclei were
counted and the percentage of nuclei contained within multinu-
cleated (.2 nuclei) syncytia was calculated, as described previously
[24].
Statistical analysis
The data presented represent mean 6 SEM of at least three
separate experiments. Differences between treatment groups were
analysed by ANOVA and a P-value of,0.05 was considered to be
statistically significant.
Results
RhoE expression is upregulated by cyclic AMP in BeWo
cells and is associated with cell fusion
BeWo cells fuse in response to treatment with cyclic AMP
[24,25]. Here we sought to determine the effect of the cell-
RhoE and Fusion of BeWo Cells
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on RhoE expression in BeWo cells. Confluent cells were treated
with low-serum medium in the presence or absence of dbcAMP at
1mM, a concentration which has previously been shown to induce
cell fusion [24]. RhoE expression was then detected by
immunoblotting. Treatment with dbcAMP significantly increased
RhoE expression after 24h compared with control (Figs. 1A and
B). To confirm stimulation of cell fusion by dbcAMP, intercellular
boundaries were visualised by labelling desmosomal protein.
Fusion was then quantified by calculating the percentage of nuclei
contained within multinucleated syncytia. As expected, treatment
with dbcAMP significantly increased fusion compared to control
(12.5% vs 3.5% and 19.0% vs 9.6% at 24h and 48h respectively,
Figs. 1C and D). We then assessed the effect of dbcAMP on RhoE
expression in JEG-3, a human choriocarcinoma cell line which
undergoes less fusion in response to cAMP compared to BeWo
[26]. In JEG-3 cells, both RhoE upregulation (Figs. 2A and 2B)
and intercellular fusion (Fig. 2C) were significantly attenuated in
response to dbcAMP treatment compared to BeWo cells. Taken
together, these results suggested a correlation between RhoE
expression and cell fusion.
Upregulation of RhoE by cyclic AMP is mediated via
protein kinase A
Cyclic AMP can exert its effects by protein kinase A (PKA)-
dependent and -independent mechanisms [27]. To explore the
role of PKA in the upregulation of RhoE by cyclic AMP we
treated BeWo cells with a PKA-selective cAMP analog, N
6-
phenyl-cAMP (Phe), for 24h and assessed RhoE expression by
immunoblotting. Treatment with Phe resulted in an induction of
RhoE expression equal to that given by dbcAMP treatment
(Fig. 3A). We then investigated the effect of the specific PKA
inhibitor 14–22 amide (PKI) on dbcAMP-induced RhoE expres-
sion. BeWo cells were pretreated with PKI or vehicle for 1h then
incubated with dbcAMP with or without PKI for 24h and assessed
for RhoE expression. PKI inhibited dbcAMP upregulation of
RhoE (Fig. 3B). These data show that RhoE upregulation by
cAMP is mediated through activation of PKA.
RhoE knockdown inhibits BeWo cell fusion
Since we found that BeWo cell fusion was associated with an
upregulation of RhoE, we hypothesised that RhoE may play an
active role in driving this process. To test this hypothesis we used
Figure 1. Effect of cyclic AMP on RhoE expression and fusion in BeWo cells. BeWo cells were treated with or without 1mM dbcAMP and
studied at the indicated times. Cell lysates were made and expression of RhoE and b-actin was assessed by immunoblotting (A) and densitometric
analysis of blots (B). Cells were fixed, immunostained for desmosomal protein (green) and counterstained with Hoechst 33258 (blue) (C) and cell
fusion was quantified (D) as described in Materials & Methods. Results are presented as mean 6 SEM for three separate experiments. *p,0.05,
**p,0.01 compared with control (determined by ANOVA).
doi:10.1371/journal.pone.0030453.g001
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were transfected with siRNA duplexes targeted to human RhoE
mRNA (RhoE siRNA) or a non-silencing control which has no
homology to any known mammalian gene, and then treated with
dbcAMP to stimulate RhoE expression. RhoE was efficiently
downregulated by transfection with RhoE siRNA, as demonstrat-
ed by an immunoblot of BeWo cell lysates following dbcAMP
treatment (Fig. 4A). Levels of b-actin were unaffected by
transfection with either RhoE or non-silencing siRNA. Densito-
metric analysis revealed that transfection with RhoE siRNA
resulted in a 73% knockdown of RhoE expression after 24h
dbcAMP treatment compared with the non-silencing control.
We next examined the effect of RhoE knockdown on BeWo cell
fusion. Cells were transfected with RhoE or control siRNA then
treated with low-serum medium containing 1mM dbcAMP. RhoE
siRNA-transfected cells showed a significant decrease in the
percentage of nuclei contained in syncytia compared with cells
transfected with non-silencing control (7.0% vs 11.9%, and 16.6%
vs 25.2%, at 24h and 48h respectively; Fig. 4B). We then
determined whether RhoE downregulation affected the expression
of hCG and placental alkaline phosphatase (PLAP), two markers
of biochemical differentiation of BeWo cells. Expression of both
these proteins was induced by dbcAMP treatment but their levels
were unchanged in RhoE siRNA-transfected cells compared to
non-silencing control following dbcAMP treatment, as assessed by
immunoblotting (Fig. 4C). These results suggest that RhoE plays a
role in BeWo cell fusion, but is dispensible for the induction of
some proteins associated with biochemical differentiation.
RhoE upregulation by cyclic AMP is inhibited by hypoxia
It has long been known that fusion of cytotrophoblasts is
inhibited under hypoxic conditions [28]. We proposed that, since
RhoE plays a role in BeWo cell fusion, its induction by dbcAMP
may be impaired under hypoxia. To test this, cells were grown to
confluence and cultured at 20% O2 (normoxia) or 1% O2
(hypoxia) for 24h, then treated with 1mM dbcAMP at 20% or 1%
O2 for a further 24h. RhoE expression was then assessed by
immunoblotting. Although 6.5–8.6% O2 is regarded as placental
normoxia [29], we used 20% O2 as normoxic conditions in these
experiments as BeWo cells have been adapted in culture to grow at
20% O2 and thus this represents normoxia for these cells. Figure 5
shows that the induction of RhoE by dbcAMP at 24h was reduced
in hypoxic conditions compared to normoxia. These data suggest
that the inhibition of BeWo cell fusion under hypoxia may be due,
at least in part, to impaired RhoE induction.
RhoE is expressed in primary human villous
cytotrophoblasts
Since RhoE plays a role in BeWo cell fusion, we addressed the
relevance of these observations to normal human trophoblast by
Figure 2. Attenuation of RhoE expression in response to cyclic AMP in JEG-3 cells. BeWo or JEG-3cells were treated with1mM dbcAMP. At the
indicated times cell lysates were made and expression of RhoE and b-actin was assessed by immunoblotting (A) with densitometric analysis of RhoE expression
normalised to b-actin expression (B). Cells were fixed, immunostained for desmosomal protein (C) and cell fusion was quantified (D) as described in Materials &
Methods. Results are presented as mean 6 SEM for three separate experiments. *p,0.05, **p,0.01 compared with BeWo cells( d e t e r m i n e db yA N O V A ) .
doi:10.1371/journal.pone.0030453.g002
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cytotrophoblasts. We found that RhoE was strongly expressed in
these cells, which fuse spontaneously in culture [5], compared with
the very weak expression in untreated, non-fusing BeWo cells
(Fig. 6), suggesting that RhoE may play a role in normal human
trophoblast functions, including fusion.
Discussion
In this study we demonstrate for the first time that RhoE is
regulated by cyclicAMP andisinvolvedinthe cyclicAMP-mediated
fusion of the BeWo human choriocarcinoma cell line. These results
suggest that RhoE may play an important role in the regulation of
trophoblast fusion in normal and/or pathological pregnancies.
Several members of the Rho GTPase family, such as RhoA,
Rac1 and cdc42, have been described in human cytotrophoblasts
and shown to play a role in their migration [13]. However, a role
for members of the Rho family of proteins in cytotrophoblast
fusion has not been reported to date. In myoblasts, RhoE is
required for intercellular fusion resulting in the formation of
myotubes. In these cells RhoE expression increases until the onset
of fusion before returning to its basal level once fusion is under way
[21]. To date, no data exist on the expression of RhoE in primary
human cytotrophoblasts or in the BeWo cell line, a well-
characterised model of human cytotrophoblast differentiation
and fusion [22]. Given its role in myoblast fusion, we hypothesised
that RhoE may also be expressed in BeWo cells and play a role in
their fusion.
Cyclic AMP treatment has long been known to promote fusion
of both primary human cytotrophoblasts [30] and BeWo cells
[24,25], and to upregulate several proteins involved in fusion,
including syncytin-1 [31], syncytin-2 [32], MFSD2A [33] and
CD9 [34]. In the present study, treatment of BeWo cells with the
cell-permeable cAMP analogue dbcAMP led to an upregulation of
RhoE, concomitant with an increase in cell fusion. Since RhoE
lacks intrinsic GTPase activity and is not regulated by GEFs and
GAPs, control of its expression level, together with post-
translational modification, is an important mechanism for the
regulation of its function within the cell. A number of different
stimuli have been shown to induce RhoE expression via
transcriptional regulation, including chemotherapeutic agents
[35], ultraviolet irradiation [36] and estradiol [37]. Phosphoryla-
tion of RhoE by ROCK1 and PKCa also upregulates its
expression by increasing its stability through prevention of
proteasomal degradation [38,39].
To our knowledge, this is the first report showing upregulation
of RhoE by cAMP. Interestingly, induction of RhoE by dbcAMP
Figure 3. Upregulation of RhoE by cyclic AMP is mediated through protein kinase A. BeWo cells were treated with 1mM dbcAMP or PKA-
selective cAMP analogue (Phe) for 24h. Cell lysates were made and expression of RhoE and b-actin was assessed by immunoblotting (A) with
densitometric analysis of RhoE expression normalised to b-actin expression (B). BeWo cells were pretreated with the specific PKA inhibitor PKI or
vehicle for 1h then treated with 1mM dbcAMP in the presence or absence of PKI. After 24h cell lysates were made and expression of RhoE and b-actin
was assessed by immunoblotting (C) with densitometric analysis of RhoE expression normalised to b-actin expression (D). Representative blots from
three separate experiments are shown.
doi:10.1371/journal.pone.0030453.g003
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Although some studies have reported that JEG-3 cells are non-
fusogenic [40,41], we, in this study, and others [26] have shown
that they do undergo some fusion in response to cAMP but at a
significantly reduced level compared to BeWo cells. These results
led us to hypothesise that this correlation between cAMP-induced
Figure 4. Effect of RhoE knockdown on BeWo cell fusion and differentiation. BeWo cells were transfected with 50nM RhoE siRNA or a non-
silencing control then treated with 1mM dbcAMP and studied at the time points indicated. Cell lysates were made and expression of RhoE and b-
actin was assessed by immunoblotting (A). Cells were also fixed and immunostained for desmosomal protein and cell fusion quantified (B) as
described in Materials & Methods. Cell lysates were also studied for expression of PLAP, b-hCG and b-actin by immunoblotting (C) with densitometric
analysis normalised to b-actin expression (D). Results are presented as mean 6 SEM for four separate experiments. *p,0.05 compared with non-
silencing control (determined by ANOVA).
doi:10.1371/journal.pone.0030453.g004
Figure 5. Effect of hypoxia on cAMP-induced RhoE expression. BeWo cells were cultured at 20% O2 (normoxia) or 1% O2 (hypoxia) for 24h,
then treated with 1mM dbcAMP at 20% or 1% O2 for a further 24h. Cell lysates were made and RhoE and b-actin expression was assessed by
immunoblotting (A) with densitometric analysis of RhoE expression normalised to b-actin expression (B). A representative blot from three separate
experiments is shown.
doi:10.1371/journal.pone.0030453.g005
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for RhoE in BeWo cell fusion. In support of this hypothesis we
found that knockdown of RhoE expression by RNA interference
resulted in a significant inhibition of BeWo cell fusion. Although
significant, the reduction in fusion we observed following RhoE
depletion was relatively modest. This may be due to upregulation
of other Rnd subfamily members in response to dbcAMP, or may
indicate the concurrent activation of alternative, Rnd subfamily-
independent pathways which also promote cell fusion. However, it
may also be the result of insufficient knockdown; although
immunoblot analysis revealed 73% knockdown, there was still
clearly some upregulation of RhoE in response to dbcAMP which
may have been sufficient to induce some fusion. As in myoblasts
[21], RhoE expression is maximal at the onset of fusion and then
declines at later time points despite a further increase in fusion,
suggesting that RhoE is required relatively early in the fusion
pathway and is no longer required once fusion is complete.
Interestingly, expression of two differentiation-associated pro-
teins, hCG and PLAP, was unaffected by RhoE knockdown,
suggesting that RhoE is required for fusion but may be dispensible
for biochemical differentiation. This supports the findings of recent
work which showed that treatment of BeWo cells with a PKA
inhibitor, H-89, led to an inhibition of fusion but had no effect on
hCG expression [42], and suggests that trophoblast fusion and
functional differentiation may be controlled by separate or
diverging pathways. Similarly, in myoblasts knockdown of RhoE
impairs myotube formation but has no effect on the expression of
myogenin and troponin T, two muscle-specific proteins [21].
Cyclic AMP can exert its effects through activation of protein
kinase A, exchange protein directly activated by cAMP (Epac) and
cAMP-gated ion channels. Using a PKA-specific cAMP analogue
and a pharmacological PKA inhibitor we found that upregulation
of RhoE by cAMP in BeWo cells is mediated through the PKA
pathway. Activation of PKA has been shown to promote
trophoblast fusion [30]. Many effects of PKA are elicited via its
phosphorylation of cyclic AMP response element binding protein
(CREB) at Ser
133 and subsequent transcription of target genes
[27]. In BeWo cells PKA-induced CREB phosphorylation leads to
increased transcription of GCM1 [43,44], a transcription factor
which is essential for trophoblast fusion. Furthermore, PKA
stimulates CREB-binding protein-mediated acetylation of GCM1,
resulting in an elevation of its activity [45]. Therefore, it is
tempting to speculate that cAMP-PKA signalling may upregulate
RhoE expression through increased expression and/or activation
of GCM1. This notion is supported by our finding that
upregulation of RhoE by cAMP is attenuated under hypoxic
conditions, since GCM1 activity is decreased in trophoblasts in
hypoxia as a result of enhanced degradation [46], and leads us to
speculate that this attenuation of RhoE expression may form part
of the mechanism by which BeWo cell fusion is inhibited in
hypoxia [47]. However, we cannot rule out the possibility that
RhoE may be upregulated by direct phosphorylation by PKA,
leading to increased stability in a manner similar to that elicited by
PKCa and ROCK1.
The mechanism by which RhoE regulates BeWo cell fusion
remains to be determined. In myoblasts, upregulation of RhoE
leads to a p190RhoGAP-mediated inhibition of RhoA and
ROCK1 activities, which are required for fusion to take place.
This may be mediated through M-cadherin which is upregulated
and accumulates at cell-cell contact sites in a RhoE-dependent
manner [21]. There are no reports documenting RhoA or
ROCK1 activities during trophoblast fusion but it has been
shown that fusion is inhibited in primary human cytotrophoblasts
transfected with antisense oligonucleotides specific for cadherin-11
[48]. Therefore it may be that RhoE may promote fusion in BeWo
cells by increasing cadherin-11 expression and/or localisation,
possibly through a mechanism involving modulation of RhoA and
ROCK1 activities. These are themes which will be explored in
future work.
In conclusion, the present study has identified RhoE as a new
target for cAMP-PKA signalling and a mediator of fusion in BeWo
cells. Our finding that RhoE is strongly expressed in isolated
primary human cytotrophoblasts indicates that further studies will
be required to fully understand the role of RhoE in trophoblast
function.
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